Abstract The Joint Research Centre of Ispra, one of the research Sites belonging to the European Commission, Directorate General JRC, was created in the late '50s, in order to steer European research on nuclear industry. It currently hosts numerous nuclear facilities, some of which are maintained in operation, while others were shutdown in past years or are currently being decommissioned. Since 2003, a Radiopharmaceutical facility has been set up at the JRC Cyclotron Laboratory, in collaboration with General Electric Healthcare, for the production and commercialization of [18F]FDG. This Radiopharmaceutical Laboratory has been the first FDG production facility to be officially authorized by the Italian Health Ministry and has been operating since 2003 without any interruption. During these years, some upgrades in the capacity and maximum activity produced by the Lab have been performed. Two different beam lines and one irradiation vault have been devoted to FDG production in order to increase the production capability. The paper, thus, is a review of Radiation Protection activities performed in the Lab during its years of operation and in particular the distribution of the dose related to the activity and the daily personal dose trend, subdivided between FDG production and Quality Control (QC), will be shown and discussed. Further, a recent internal contamination dose assessment campaign will be presented and the results discussed.